Impact of antibiotic exposure on the risk of colorectal cancer

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 5, 2015, Pages 534-542

  Boursi, Ben ^a,b,c   Haynes, Kevin ^a   Mamtani, Ronac ^a   Yang, Yu Xiao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibiotic; Cancer; Colorectal; Penicillin; Pharmacoepidemiology; Risk factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM; CASE CONTROL STUDY; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; INCIDENCE; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INCIDENCE; MALE; MICROBIOTA; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; UNITED KINGDOM;

EID: 84928183077     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3765     Document Type: Article

References (39)

1. Zhu Q, Gao R, Qin H. The role of gut microbiota in the pathogenesis of colorectal cancer. Tumor Biol 2013; 34: 1285-1300.
2. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. Plos 2011; 6: e20447.
3. Abreu MT, Peek RM. Gastrointestinal malignancy and the microbiome. Gastroenterology 2014. doi:10.1053/j.gastro.2014.01.001.
4. Reddy BS, Narisawa T, Wright P, Vukusich D, Weisburger JH, Wynder EL. Colon carcinogenesis with Azoxymethane and Dimethylhydrazine in germ free rats. Cancer Res 1975; 35: 287-290.
5. Vannucci L, Stepankova R, Kozakova H, Fiserova A, Rossmann P, Tlaskalova-Hogenova H. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Onc 2008; 32: 609-617.
6. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. Plos 2011; 6: e16393.
7. Brim H, Yooseph S, Zoetendal EG, et al. Microbiome analysis of stool samples from African Americans with colon polyps. PLoS One 2013; 8(12): e81352.
8. Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. Gastroenterology 2013; 29: 85-91.
9. Russell WR, Duncan SH, Flint H. The gut microbial metabolome: modulation of cancer risk in obese individuals. Proc Nutr Soc 2013; 72: 178-188.
10. Kamada N, Seo S, Chen G, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013; 13: 321-335.
11. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One 2013; 8(8): e70803. doi:10.1371/journal.pone.0070803.
12. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 5: 120-123.
13. Hajishengallis G, Darveau R, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol 2012; 10: 717-725.
14. Riley DR, Sieber KB, Robinson KM, et al. Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples. Plos 2013; 9: e1003107.
15. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6(11): e280. doi:10.1371/journal.pbio.0060280.
16. O'Sullivan O, Coakley M, Lakshminarayanan B, et al. Alterations in intestinal microbiota of elderly irish subjects post-antibiotic therapy. J Antimicrob Chemother 2013; 68: 214-221.
17. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010; 156: 3216-3223.
18. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1: 56-66.
19. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. Plos 2010; 5: e9836.
20. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267.
21. Lode H, Von der Hoh N, Ziege S, Borner K, Nord C. Ecological effects of linezolid versus amoxicillin/clavulonic acid on the normal intestinal microflora. Scand J Infect Dis 2001; 33: 899-903.
22. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16s rRNA sequencing. PLoS Biol 2008. doi:10.1371/journal.pbio.0060280.
23. Haeseker MB, Dukers-Muijrers N, Hoebe C, Bruggeman CA, Cals JW, Verbon A. Trends in antibiotic prescribing in adults in Dutch general practice. PLoS One 2012; 7(12): e51860.
24. Adriaenssens N, Coenen S, Versporten A, et al. European surveillance of antimicrobial consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011; 66(6): 3-12.
25. Kilkkinen A, Rissanen H, Klaukka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer 2008; 123: 2152-2155.
26. Lubin JH, Gail MH. Biased selection of controls for case-control analysis of cohort studies. Biometrics 1984; 40: 63-75.
27. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Safe 2009; 18: 76-83.
28. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12: 171-177.
29. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
30. Hollowell J. The general practice research database: quality of morbidity data. Popul Trends 1997; 87: 36-40.
31. Van-Staa TP, Wegman S, De-Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285: 1850-55.
32. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the general practice research database. Pharmacoepidemiol Drug Saf 2005; 14: 443-451.
33. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 2013; 108: 208-215.
34. Horwitz RI, Feinstein AR. The problem of "protopathic bias" in case control studies. Am J Med 1980; 68(2): 255-258.
35. Lai HC, Lin CC, Cheng KS, et al. Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a population based cohort study. Gastroenterology 2014; 146: 129-37.
36. Wang JL, Chang CH, Lin JW, Wu LC, Chuang LM, Lai MS. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus. Int J Cancer 2014; 135(4): 956-67.
37. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490(7418): 55-60.
38. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498(7452): 99-103.
39. Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2009; 18: 730-736.